RU2015137828A - Стабильное и лиофилизированное фармацевтическое средство, содержащее нокатиацин - Google Patents

Стабильное и лиофилизированное фармацевтическое средство, содержащее нокатиацин Download PDF

Info

Publication number
RU2015137828A
RU2015137828A RU2015137828A RU2015137828A RU2015137828A RU 2015137828 A RU2015137828 A RU 2015137828A RU 2015137828 A RU2015137828 A RU 2015137828A RU 2015137828 A RU2015137828 A RU 2015137828A RU 2015137828 A RU2015137828 A RU 2015137828A
Authority
RU
Russia
Prior art keywords
stable
product containing
nocatiacin
lyophilized pharmaceutical
pharmaceutical product
Prior art date
Application number
RU2015137828A
Other languages
English (en)
Russian (ru)
Inventor
Ицзюнь ЧЭНЬ
Original Assignee
Наньцзин Байотика Фармасьютикал Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Наньцзин Байотика Фармасьютикал Компани filed Critical Наньцзин Байотика Фармасьютикал Компани
Publication of RU2015137828A publication Critical patent/RU2015137828A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Inorganic Chemistry (AREA)
RU2015137828A 2013-02-05 2013-09-12 Стабильное и лиофилизированное фармацевтическое средство, содержащее нокатиацин RU2015137828A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2013100448189A CN103040769A (zh) 2013-02-05 2013-02-05 一种稳定的诺卡沙星粉针冻干剂
CN201310044818.9 2013-02-05
PCT/CN2013/083366 WO2014121611A1 (zh) 2013-02-05 2013-09-12 一种稳定的诺卡沙星粉针冻干剂

Publications (1)

Publication Number Publication Date
RU2015137828A true RU2015137828A (ru) 2017-03-10

Family

ID=48053782

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015137828A RU2015137828A (ru) 2013-02-05 2013-09-12 Стабильное и лиофилизированное фармацевтическое средство, содержащее нокатиацин

Country Status (11)

Country Link
US (1) US9616125B2 (enExample)
EP (1) EP2954894B1 (enExample)
JP (1) JP6063064B2 (enExample)
KR (1) KR101801177B1 (enExample)
CN (1) CN103040769A (enExample)
AU (1) AU2013377601B2 (enExample)
CA (1) CA2900114C (enExample)
DK (1) DK2954894T3 (enExample)
ES (1) ES2749474T3 (enExample)
RU (1) RU2015137828A (enExample)
WO (1) WO2014121611A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103040769A (zh) * 2013-02-05 2013-04-17 南京碧迪可医药科技有限公司 一种稳定的诺卡沙星粉针冻干剂
CN104771359A (zh) * 2015-04-02 2015-07-15 南京正大天晴制药有限公司 一种稳定的盐酸莫西沙星注射液
CN107469068B (zh) * 2017-08-04 2021-06-22 南京碧迪可医药科技有限公司 一种硫肽环素的药物组合物
EP4467127A4 (en) * 2022-03-24 2025-05-21 LG Chem, Ltd. Injectable preparation comprising isoxazoline derivative, and preparation method therefor

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020055465A1 (en) * 2000-08-14 2002-05-09 Wenying Li Nocathiacin antibiotics prepared by biotransformation or chemical methods
US20040042972A1 (en) * 2002-04-11 2004-03-04 Medimmune Vaccines, Inc. Spray freeze dry of compositions for intranasal administration
US8436190B2 (en) * 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
US20080132500A1 (en) * 2006-10-20 2008-06-05 Kun Liu Antibiotic compounds
GB0821806D0 (en) * 2008-11-28 2009-01-07 Circassia Ltd Compositions with reduced dimer formation
US9062094B2 (en) * 2010-01-22 2015-06-23 Ascendis Pharma As Dipeptide-based prodrug linkers for aliphatic amine-containing drugs
CN102018953B (zh) * 2010-11-18 2013-05-01 南京碧迪可医药科技有限公司 含诺卡沙星抗生素的药物组合物
CN103040769A (zh) * 2013-02-05 2013-04-17 南京碧迪可医药科技有限公司 一种稳定的诺卡沙星粉针冻干剂
CN103040770B (zh) * 2013-02-05 2016-08-17 南京碧迪可医药科技有限公司 一种诺卡沙星冻干粉针剂的制备方法

Also Published As

Publication number Publication date
EP2954894A1 (en) 2015-12-16
CN103040769A (zh) 2013-04-17
WO2014121611A1 (zh) 2014-08-14
CA2900114A1 (en) 2014-08-14
AU2013377601B2 (en) 2017-02-02
JP2016507535A (ja) 2016-03-10
KR101801177B1 (ko) 2017-11-24
US20150374824A1 (en) 2015-12-31
US9616125B2 (en) 2017-04-11
EP2954894B1 (en) 2019-08-14
JP6063064B2 (ja) 2017-01-18
CA2900114C (en) 2017-06-13
AU2013377601A1 (en) 2015-08-27
EP2954894A4 (en) 2016-06-15
DK2954894T3 (da) 2019-08-26
ES2749474T3 (es) 2020-03-20
KR20150113201A (ko) 2015-10-07

Similar Documents

Publication Publication Date Title
ES2636680T3 (es) Preparación liofilizada de toxina botulínica
CN102872011B (zh) 包含(s)-4-羟基-2-氧代-1-吡咯烷乙酰胺的药物组合物
ES2965722T3 (es) Compuestos excipientes reductores de la viscosidad para formulaciones proteicas
JP2015527402A5 (enExample)
EA201492021A1 (ru) Антительный состав
RU2016105462A (ru) Способы и композиции, которые обеспечивают модуляцию иммунных ответов, связанных с введением биофармацевтического лекарственного средства
NZ730821A (en) Stable protein solution formulation containing high concentration of an anti-vegf antibody
JP2019536761A5 (enExample)
TW202337489A (zh) 於腦脊髓膜內遞送芳基硫酸酯酶a之方法及組合物
EA200870264A1 (ru) Композиция антител
US11225652B2 (en) Thrombin solution and methods of use thereof
JP2002363097A (ja) 安定化された凍結乾燥型医薬組成物
HRP20240197T1 (hr) Farmaceutski pripravak koji sadrži protuvirusni derivat dihidrokinazolina koji ima konfiguraciju s na položaju 4
RU2017125931A (ru) Фармацевтическая композиция, содержащая плазминоген, и ее применение
CN102068685A (zh) 一种特利加压素制剂及其制备方法
RU2017101667A (ru) Фармацевтические композиции
HRP20201242T1 (hr) Tekući farmaceutski pripravak
JP2015508403A5 (enExample)
EA202092926A2 (ru) Лиофилизированные составы, содержащие фактор ix
RU2014137096A (ru) Перорально вводимая фармацевтическая композиция
CN103655487B (zh) 一种注射用前列地尔冻干乳剂
NZ731518A (en) Formulations of a pi3k/mtor-inhibitor for intravenous administration
JP2016113461A5 (enExample)
JP6063064B2 (ja) 安定したノカチアシン凍結乾燥製剤
JP2016507535A5 (enExample)